Orchestra BioMed (OBIO) announced the appointment of Christopher Cleary to its Board of Directors as an independent member, effective as of January 30, 2025. Cleary brings over three decades of experience in corporate development, mergers, acquisitions, strategic investments and structured R&D collaborations, having significantly impacted the medical technology industry through his strategic leadership and visionary approach. After seven years of dedicated service on Orchestra BioMed’s Board of Directors, Eric Rose, M.D. will transition to Board Member Emeritus and Strategic Advisor to Orchestra BioMed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OBIO: